Techniques for implementing identification and management of unsafe optimizations are disclosed. A method of the disclosure includes receiving, by a managed runtime environment (MRE) executed by a processing device, a notice of misprediction of optimized code, the misprediction occurring during a runtime of the optimized code, determining, by the MRE, whether a local misprediction counter (LMC) associated with a code region of the optimized code causing the misprediction exceeds a local misprediction threshold (LMT) value, and when the LMC exceeds the LMT value, compiling, by the MRE, native code of the optimized code to generate a new version of the optimized code, wherein the code region in the new version of the optimized code is not optimized.

An execution environment may have a monitoring, analysis, and feedback loop that may configure and tune the execution environment for currently executing workloads. A monitoring or instrumentation system may collect operational and performance data from hardware and software components within the system. A modeling system may create an operational model of the execution environment, then may determine different sets of parameters for the execution environment. A feedback loop may change various operational characteristics of the execution environment. The monitoring, analysis, and feedback loop may optimize the performance of a computer system for various metrics, including throughput, performance, energy conservation, or other metrics based on the applications that are currently executing. The performance model of the execution environment may be persisted and applied to new applications to optimize the performance of applications that have not been executed on the system.

The variable domain data access control system and method described herein use the same variable domain to describe a data security model and a variable domain data model, such as a product configuration model. A variable domain is a set of resource data that can be described using a logical relationship data structure. The variable domain utilizes logical relationship expressions, such as a Boolean logic language, to define resource data in terms of parts, rules and/or attributes, and any other property that can be accessed for viewing, manipulation, or other purposes. The data security model represents an access control list (ACL) that includes security attributes as resource data and uses the same data structure and logical relationship expressions as an associated variable domain data model. An application, such as a configuration engine, can be used to create controlled access to the variable domain data model using the data security model.

A method uses a firmware interface setup program for a selected compute node (“node”) to cause a firmware interface to enable a trusted platform module (TPM) on the selected node to receive a physical presence (PP) signal. The selected node is selected from a plurality of nodes within a multi-node chassis, wherein each node includes a firmware interface and a TPM. A device within the multi-node chassis is manually actuated to transmit a PP signal to each of the plurality of nodes, such that each node receives the PP signal. The PP signal is asserted to the TPM of the selected node in response to both enabling the TPM of the selected node to be able to receive the PP signal and receiving the PP signal. Still further, the method allows modification of a security setting of the selected node in response to the TPM receiving the PP signal.

A method is provided to process data so that the data can be externally stored with minimized risk of information leakage. A framework (virtual execution framework) based on virtual machines (VMs) is utilized as a substitute for a trusted institution. Encryption of consolidated data can reduce risk of information leakage and enhance security. Since the virtual execution framework can control connection and direction of communication, financial institutions are allowed to apply encryption to data on their own, which makes the data further appropriate for external storage. By allowing financial institutions to apply their own decryption, it is possible to prevent one of two financial institutions from retrieving externally stored data into the external execution framework without intervention of the other. Additionally, associated acting subjects can be provided with freedom depending on the degree of information leakage risk.

Techniques are described to transmit commands to a display device. The commands can be transmitted in header byte fields of secondary data packets. The commands can be used to cause a target device to capture a frame, enter or exit self refresh mode, or reduce power use of a connection. In addition, a request to exit main link standby mode can cause the target enter training mode without explicit command to exit main link standby mode.

There is provided a power management apparatus including: a managed appliance registering unit carrying out authentication on an electronic appliance connected to a power network and registering an electronic appliance for which the authentication has succeeded as a managed appliance, a control unit controlling operation of the managed appliance and supplying of power to the managed appliance, a managed appliance information acquiring unit acquiring, from the managed appliance, as managed appliance information, at least any of appliance information including identification information that is unique to the electronic appliance, information indicating an operation state of the electronic appliance, information indicating an usage state of the electronic appliance and power information of the electronic appliance, and an appliance state judging unit judging a state of the managed appliance based on the managed appliance information acquired by the managed appliance information acquiring unit.

A system, methods and server for monitoring health and safety of individuals in a population and sending alert notifications when exceptions are detected include comparing biometric data obtained from the individuals to a biometric model generated for the individual through computer-learning methods. Biometric data may be gathered by wireless biometric sensor devices which transmit biometric data to receiver devices, which relay the biometric data to a server. The biometric model may be maintained in the server and include nominal and threshold biometric parameters for each individual based on biometric sensor data gathered or analyzed over a period of time. An alert may be issued by the server when an individual's biometric data is outside a threshold in the biometric model. The transmitted alert may depend upon the nature of the exception, user settings and past notification experience. Alerts may be escalated when not answered within defined durations.

Systems and methods for processing magnetic resonance imaging (MRI) data are provided. A method includes receiving MRI data comprising a plurality of k-space points and deriving a plurality of image data sets based on the MRI data, each of the plurality of MRI image sets obtained by zeroing a different one of the plurality of k-space points. The method further includes computing image space metric values for each of the plurality of image data sets and adjusting a portion of the MRI data associated with ones of the image space metric values that fail to meet a threshold value to yield adjusted MRI data.

The disclosed embodiments relate to pulse oximetry. An exemplary pulse oximeter comprises a probe that is adapted to be attached to a body part of a patient to create a signal indicative of an oxygen saturation of blood of the patient, and a processor that is adapted to receive the signal produced by the probe, to calculate an SPO2 value based on the signal, to detect a plurality of pattern types of SPO2 indicative of pathophysiologic events, and to produce an output indicative of a detected one of the plurality of pattern types.

A magnetic resonance imaging apparatus includes an acoustic control unit and an image data acquisition unit. The acoustic control unit applies a gradient magnetic field for controlling a sound in synchronization with a signal representing a respiratory body motion. The image data acquisition unit acquires imaging data by subsequently imaging to control the sound and generate image data based on the imaging data.

Velocity of MR-imaged fluid flows is measured. Data representing a measure of distance traveled by flowing fluid appearing in at least two MR images of a subject's tissue taken at different respective imaging times is generated. Data representing at least one fluid velocity measurement of the flowing fluid is generated by calculating at least one instance of distance traveled by the fluid divided by elapsed time during travel based on different respective imaging times. Data representing at least one fluid velocity measurement is then output to at least one of: (a) a display screen, (b) a non-transitory data storage medium, and (c) a remotely located site.

Systems and methods for imaging within depth layers of a tissue include illuminating light rays at different changing wavelengths (frequencies), collimating illuminated light rays using a collimator, and splitting light rays using a beam splitter, such that some of the light rays are directed towards a reference mirror and some of the rays are directed towards the tissue. The systems and methods further include reflecting light rays from the reference mirror towards the imager, filtering out non-collimated light rays reflected off the tissue by using a telecentric optical system, and reflecting collimated light rays reflected off the tissue towards the imager, thus creating an image of an interference pattern based on collimated light rays reflected off the tissue and off the reference mirror. The method may further include creating full 2D images from the interference pattern for each depth layer of the tissue using Fast Fourier transform.

An intracorporeal marker, for marking a site within living tissue of a host, includes an outer body portion of biodegradable material. An inner body portion is located in the outer body portion. The inner body portion includes biological material that becomes calcified in the living tissue of the host over time. An agent interacts with the biological material to promote calcification of the biological material of the inner body portion in the living tissue of the host.

A three dimensional imaging system includes a first laser emitting light at a first wavelength, and a scanner for scanning the laser light in a pattern on the target area. A photo detector receives light reflected from the target area as a contrasted vein image, resulting from differential absorption and reflection therein of the first wavelength of light. The intensity of the first laser is incrementally increased, and the photo detector thereby receives a plurality of contrasted vein images, each being at incrementally distinct depths beneath the target skin surface. Image processing is performed on the plurality of vein images to successively layer the veins in the images according to their depth, to create a single processed vein image. A second laser emitting a second wavelength of light is used in combination with the scanner to project the processed vein image onto the target area to overlay the veins therein.

A device for fluorescence-based imaging and monitoring of a target comprising: a light source emitting light for illuminating the target, the emitted light including at least one wavelength or wavelength band causing at least one biomarker associated with the target to fluoresce; and a light detector for detecting the fluorescence.

A device is described for measuring electrical characteristics of biological tissues with one or a plurality of electrodes and a processor controlling the stimulation and measurement in order to detect the presence of abnormal tissue masses in the breast and determine probability of tumors containing malignant cancer cells being present in a breast. The device has the capability of providing the location of the abnormality, at least to the quadrant. Either single or multiple source electrodes can be used. Either palpable lumps can be evaluated or screening or breasts, whether with palpable masses or not, can be accomplished. The method for measuring electrical characteristics includes placing electrodes and applying a voltage waveform in conjunction with a current detector. A mathematical analysis method is then applied to the collected data, which computes spectrum of frequencies and correlates magnitudes and phases with given algebraic conditions to determine mass presence and type.

Provided are a three-dimensional (3D) ultrasound system and a method for operating the 3D ultrasound system, which are capable of intuitively displaying the abnormality of an object by determining a grade by comparing measurement data obtained by measuring ultrasound data relating to the object and displaying the measurement data in a different way based on the determined grade.

An information processing method includes the following steps: applying a pattern matching process on the body motion signal information, and extracting rhythm cycle candidate waves which are rhythm cycle candidates related to the rhythmic motion; performing −1 or more times integration on the body motion signal information to obtain a motion trajectory, and performing coarse-graining on the motion trajectory to produce an auxiliary wave; superimposing the rhythm cycle candidate waves which are extracted in the process of extracting the cycle candidate waves, on the obtained auxiliary wave, and selecting a cycle of a rhythm cycle candidate wave which has a peak in the auxiliary wave, as a true cycle; and finally obtaining a result of the processing.

Transcranial magnetic stimulation (TMS) is a remarkable tool for probing the brain. However, it is still unclear why specific regions in the cortex are excitable by TMS while others are not. This invention provides methods and tools for the design of efficient magnetic stimulators. Such stimulators can excite neuronal networks that were not sensitive to stimulation until now. Stimulation can be carried out both in-vitro and in-vivo. Novel systems and techniques of this invention will enable both treatment and diagnostics by stimulating regions of the brain or neuronal assemblies that were previously unaffected by TMS.

Apparatus and methods are described including acquiring a first set of extraluminal images of a lumen, using an extraluminal imaging device. At least one of the first set of images is designated as a roadmap image. While an endoluminal device is being moved through the lumen, a second set of extraluminal images is acquired. A plurality of features that are visible within images belonging to the second set of extraluminal images are identified. In response to the identified features in the images belonging to the second set of extraluminal images, a plurality of local calibration factors associated with respective portions of the roadmap image are determined. Other applications are also described.

A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an active ingredient, and a method of muscle relaxation comprising administering a therapeutically effective amount of the phenylcarbamate compound, are provided.

The subject of the present invention are novel esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them and their use in the production of drugs for the prophylaxis or treatment of oncogenic diseases and diseases connected with increased cell proliferation.

A feed additive includes at least one of p-thymol, a salt derivative and an ester derivative thereof for animals.

Provided is a method for producing a chlorogenic acids composition having a reduced caffeine content and good taste and favor, capable of efficiently recovering high purity of chlorogenic acids from a chlorogenic acids-containing composition. The method for producing a purified chlorogenic acids composition comprises a step A of bringing a chlorogenic acids-containing composition into contact with a cation exchange resin; a step B of bringing the liquid obtained in the step A into contact with an anion exchange resin; and a step C of bringing an eluent into contact with the anion exchange resin after the step B.

A phenyl alkyl carbamate derivative compound and a pharmaceutical composition containing the compound are provided. More specifically, the phenyl alkyl carbamate derivative compound and a pharmaceutically acceptable salt thereof, a composition for muscle relaxation containing the phenyl alkyl carbamate derivative compounds and/or pharmaceutically acceptable salt thereof as an active ingredient, and a method of muscle relaxation comprising administering a pharmaceutically effective amount of the phenyl alkyl carbamate derivative compound and/or a pharmaceutically acceptable salt thereof to a subject in need of to a subject in need of, are provided.

Provided is a gem-dinitro ester compound, represented by Formula 1 below: wherein R is a substituted or unsubstituted straight-chain or side-chain alkyl group of C2˜C12.

Provided is an amide ester that is useful as an intermediate manufacturing product for an aroma compound such as spilanthol or the like. Also provided is a spilanthol manufacturing method using said amide ester. High-purity spilanthol can be manufactured by reacting an amide ester represented by general formula (1) with a basic compound. (In the formula, R1 represents a C1-6 alkyl group or a phenyl group that may be substituted with a C1-4 alkyl group, a C1-4 alkoxy group, or a halogen atom; R2 represents a C1-8 hydrocarbon group; and the wavy lines represent cis configurations, trans configurations, or a mixture of the two configurations.)

The present embodiments disclose the preparation of hyperpolarized 13C dialkyl succinate compounds and hyperpolarized 13C dialkyl fumarate compounds and their use in real time, in vivo metabolic imaging of the TCA cycle.

The present invention describes chemical systems and methods for silylating aromatic organic substrates, said system comprising a mixture of (a) at least one organosilane and (b) at least one strong base, said system being substantially free of a transition-metal compound, and said methods comprising contacting a quantity of the organic substrate with a mixture of (a) at least one organosilane and (b) at least one strong base, under conditions sufficient to silylate the aromatic substrate; wherein said system is substantially free of a transition-metal compound.

A porous ceramic matrix contains a plurality of ceramic particles adhered to each other, and a plurality of channels defined by surfaces of neighboring ceramic particles, the channels each having an average diameter of 0.5-2.5 μm. Preferred ceramics also have a porosity of 25.0-40.0%, a Darcy's Permeability of 1.57-34.8×10−14 m2, and a mechanical strength of 25-64 MPa. Also disclosed is a method of preparing such a porous ceramic matrix, comprising providing a pellet containing ceramic particles that are coated with a monomer, a catalyst, and a binder; polymerizing the monomer in the solid state by heating, then carbonizing and sintering the pellet.

A method of manufacturing a water repellent film includes, before a formation step of forming an organic film on a substrate using a silane coupling agent by a vapor phase deposition method under film formation conditions, a step of specifying the film formation conditions using a test substrate of a same material as the substrate used in the formation step. The film formation condition specifying step includes: specifying film formation temperature to be not lower than a temperature at which the silane coupling agent evaporates and to be lower than a temperature at which the silane coupling agent bumps; and forming an organic film of the silane coupling agent on the test substrate at the specified film formation temperature, measuring by optical microscopic observation a time at which a bead of surplus water repellent material is formed, and specifying the film formation duration to be shorter than the measured time.

Provided are a coating composition for low refractive layer including fluorine-containing compound of the following Chemical Formula 1, an anti-reflection film using the same, and a polarizer and an image display device including the same, wherein the fluorine-containing compound of the following Chemical Formula 1 has a low refractive index of 1.28 to 1.40, thereby making it possible to easily adjust a refractive index of the anti-reflection film and be usefully used as a coating material of the anti-reflection film having an excellent mechanical property such as durability, or the like.

A silane compound having a secondary amino group protected with a specific silyl group is useful as silane coupling agent, resin additive, textile treating agent, surface treating agent, paint additive, and adhesive.

A dual end glycerol (meth)acrylate-modified silicone having formula (I): R1Me2SiO(R22SiO)aSiMe2R1 is novel. R1 is a mixture of 70-95 mol % of a group having formula (i) and 30-5 mol % of a group having formula (ii) wherein R3 is H or methyl, R2 is a monovalent hydrocarbon group which may be halogenated, Me stands for methyl, and a is an integer of 10-300.

The present invention relates to photochromic materials that include one or more indeno-fused naphthopyrans that have particular groups at the 7, 11, and 13 positions thereof, and at the position alpha to the oxygen of the pyran ring thereof. With some embodiments, hydrogen or an alkoxy group is bonded to the 7 position, an optionally substituted phenyl is bonded to the 11 position, two alkyl groups are bonded to the 13 position, and two optionally substituted phenyl groups are bonded to the position alpha to the oxygen of the pyran ring of the indeno-fused naphthopyran compound. The 13 position of the indeno-fused naphthopyrans is free of ether groups in which an ether oxygen is bonded to the 13 position, and hydroxyl. The present invention also relates to photochromic articles and compositions that include such indeno-fused naphthopyrans.

Provided are a novel 1,2-bis(dialkylphosphino)-4,5-(methylenedioxy)benzene derivative that forms a metal complex having particularly high asymmetry induction capacity and catalytic activity on β-dehydroamino acids, a method for manufacturing the same, a metal complex having this 1,2-bis(dialkylphosphino)-4,5-(methylenedioxy)benzene derivative as a ligand, and an asymmetric hydrogenation method using this metal complex. A 1,2-bis(dialkylphosphino)-4,5-(methylenedioxy)benzene derivative represented by general formula (1). (In the formula, R1 and R2 represent an alkyl group having 1-10 carbon atoms, and R1 and R2 have different numbers of carbon atoms.)

A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt.

The present invention is directed to 5-sec-butyl-2-(2,4-dimethyl-cyclohex-3-enyl)-5-methyl-[1,3]dioxane and a novel process for making the same.

The present invention relates to new salts of 6-(propyl-(2-thiophen-2-ylethyl)amino)tetralin-1-ol(rotigotine), their use as a medicament, for example for the treatment of CNS disorders like Parkinson Disease, RLS, fibromyalgia and/or depression, in particular through electromotive administration. The present invention relates to pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of rotigotine to at least one target tissue. The formulations are further characterized by good to excellent solubility of the salts in aqueous solutions.

The invention relates to a process for preparing 1-aryl-pyrazol-3-one intermediates, tautomers, and salts thereof, to novel intermediates, and to the use of the intermediates in the preparation of sigma receptor inhibitors.

A polymer, optionally made from renewable sources, comprising a specific chemical structure that is a result of the polymerization of α-hydroxycarbonyl compounds (alpha-hydroxycarbonyl compounds), particularly α-hydroxyaldehydes (alpha-hydroxyaldehydes) and α-hydroxyketones (alpha-hydroxyketones), or glycolaldehyde. A method of polymerization, the method comprising the step of reacting trimethylsilyl trifluoromethanesulfonate with the cyclic dimer of one or more α-hydroxycarbonyl compounds. A method of making said polymer, the method comprising dehydrating a cyclic dimer of one or more α-hydroxycarbonyl compounds. An end-capped polymer made from one or more α-hydroxycarbonyl compounds and terminal end-cap groups.

The present invention provides a diaryl sulfone compound represented by Formula (1) below: wherein R1 to R4 and R1' to R4' are the same or different; each represents hydrogen, C1-4 alkyl, or halogen; and R5 is (thio)glycidyl, acryloyl, or the like; and a method for producing the same. According to the present invention, a novel compound useful as a monomer for producing synthetic resin having a high refractive index and excellent transparency for optical materials can be efficiently produced with a simple production process, using an inexpensive material as a starting material.

A process for the production of 1,4-butanediol and tetrahydrofuran by catalytic hydrogenation of dialkyl maleates includes the following steps: a) hydrogenating a stream of dialkyl maleate in a first stage of reaction over suitable catalysts to produce dialkyl succinate;b) further hydrogenating the dialkyl succinate in a second stage of reaction, by using a different suitable catalyst, for producing mainly 1,4-butanediol, together with gamma-butyrolactone and tetrahydrofuran as co-products. In both stages of reaction the conditions, as hydrogen/organic feed ratio, pressure and temperature, are such to maintain the reactors in mixed liquid/vapor phase.

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 bicyclic amines of triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-3 cycloalkenyl triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II, III and IV: wherein X can be a C4-8 cycloalkyl, C4-8 cycloalkenyl, C4-9 spirocycloalkyl, C4-9 spirocycloalkenyl, C4-8 oxacycloalkyl, C4-8 dioxacycloalkyl, C6-8 oxacycloalkenyl, C6-8 dioxacycloalkenyl, C6-9 oxaspirocycloalkyl, or C6-9 oxaspirocycloalkenyl ring. These compounds are useful for the treatment of HIV and AIDS.

Provided are methods for the treatment of a rheumatic disease, such as rheumatoid arthritis, ankylosating spondylitis and/or polymyalgia rheumatic, by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof wherein the treatment is administered once daily for at least about two weeks. Also provided are methods for the treatment of osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof wherein the treatment is administered once daily for at least about two weeks.

A stigmasterol-rich phytosterol composition is prepared wherein the composition comprises at least 50% stigmasterol, based on the total weight of phytosterols, no more than 1000 ppm water, no more than 50 ppm ethanol, and wherein stigmasterol is at least 98% in the anhydrous form. A ready-to-freeze beverage is provided comprising the stigmasterol-rich composition and water, with optional additives. A frozen beverage is prepared from the ready-to-freeze beverage as a pourable slush. There are further provided processes to prepare the ready-to-freeze beverage and the frozen slush beverage.

The present invention provides a method to label phospholipids in vivo based on the metabolic incorporation of an alkynyl- or azido-labeled metabolic precursor into phospholipids. The resulting phospholipids have alkynyl or azido moieties, which, upon reaction with a labeled azide or alkyne, respectively, form labeled compounds that can be visualized using optical or electron microscopy with high sensitivity and spatial resolution in cells or tissue. The present method provides a valuable tool for imaging phospholipid synthesis, turnover and subcellular localization in cultured cells as well as in animals.

Tissue slices and whole organisms offer substantial challenges to fluorescence imaging. Autofluorescence and absorption via intrinsic chromophores, such as flavins, melanin, and hemoglobins, confound and degrade output from all fluorescent tags. An “optical window,” farther red than most autofluorescence sources and in a region of low hemoglobin and water absorbance, lies between 650 and 900 nm. This valley of relative optical clarity is an attractive target for fluorescence-based studies within tissues, intact organs, and living organisms. Novel fluorescent tags were developed herein, based upon a genetically targeted fluorogen activating protein and cognate fluorogenic dye that yields emission with a peak at 733 nm exclusively when complexed as a “fluoromodule”. This tool improves substantially over previously described far-red/NIR fluorescent proteins in terms of brightness, wavelength, and flexibility by leveraging the flexibility of synthetic chemistry to produce novel chromophores.